Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
Date:4/28/2009

Conference Call and Webcast at 11:00 a.m. Eastern Time

THE WOODLANDS, Texas, April 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2009.

"Our pipeline of novel drug candidates continues to advance in line with our expectations," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "During the quarter, we also restructured our operations to conserve capital and concentrate our resources on advancing the most promising programs in our pipeline."

Key Developments

  • Lexicon completed a drug-drug interaction study of LX2931 with methotrexate in patients with rheumatoid arthritis in March 2009. Top line results from the trial indicated that LX2931 was well tolerated in combination with methotrexate, and no drug-drug interactions were observed. In addition, Lexicon will present Phase 1 data for LX2931 at the European League Against Rheumatism (EULAR) annual meeting on June 13, 2009.
  • Lexicon continues to enroll patients in a Phase 2a clinical trial of its LX1031 drug candidate for non-constipating

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015  MEI Pharma, Inc. (Nasdaq: MEIP ), ... therapies for cancer, announced today that Daniel P. Gold ... the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, ... Meridien in New York . A ... www.meipharma.com . A replay will be available approximately one hour ...
(Date:8/4/2015)... Pharma Ltd. (the "Company") (NASDAQ: NTEC ), a ... on its proprietary Accordion Pill platform technology, today announced ... the United States of 5,025,000 of ... of $6.00 per ordinary share, before underwriting discounts and ... by the Company.  In addition, the Company has granted ...
(Date:8/4/2015)... Medical Services Holdings Limited ("Concord Medical", or the "Company") (NYSE: ... of the largest network of radiotherapy and diagnostic imaging centers ... release its financial results for the second quarter of 2015 ... Management will hold a conference call to discuss the results ... 2015 (8:00 p.m. in Beijing / ...
Breaking Medicine Technology:MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2
... 26, 2011 Science, public health, and ... in this document is designed for credentialed journalists. Release dates ... 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... regulatory or enforcement actions due to legal limitations. ...
... 26, 2011 Pearl Therapeutics Inc. presented ... demonstrating that the dual bronchodilator combination product, PT003 ... to Spiriva® HandiHaler® (tiotropium bromide inhalation powder). IC is ... be predictive of improvement in exercise performance in patients ...
Cached Medicine Technology:FDA News & Notes - Week of September 26, 2011 2Pearl Therapeutics' Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva® 2Pearl Therapeutics' Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva® 3Pearl Therapeutics' Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva® 4
(Date:8/4/2015)... , ... August 04, 2015 , ... 24/7 Care ... Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of Veteran’s ... that 24/7 Care At Home’s agency is well on the path to meeting the ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... those entering kindergarten. All required immunizations are covered for members under the Healthchek ... children who aren’t caught up with their immunizations may not be allowed to ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, a leading ... announced that John Munro, a 15-year veteran of the eDiscovery services industry, has ... , “I am thrilled to join Discovia at this important point in its ...
(Date:8/4/2015)... St. Louis, Missouri (PRWEB) , ... August 04, ... ... Automated Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership ... 30-year track record of sales success at technology companies and expanding global markets ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma ... has come back: Retreatment may be a viable option. Surviving Mesothelioma has just ... , According to surgeons at the University of New South Wales, ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2
... Function Drinks,announced today the launch of their ... on supporting sexual health. Function: Night Life ... amino acid, tyrosine, to provide,the building blocks ... with reward and desire. Epimedium, niacin and,cnidium ...
... for ... consumers, PRINCETON, N.J., June ... care products,announced today that its key product line, MEDIHONEY(TM) Wound & Burn,Dressings ... counter (OTC) sales. This will provide consumers with expanded,access to the products ...
... Kiner has,been named vice president and general manager ... In this new role, Stewart is responsible for,providing ... senior market lines of business, including Medicare Advantage ... Kiner will report to,Karen Vigil, senior vice president ...
... 24 Speaker Nancy Pelosi,issued the following statement ... Act, which passed the House this afternoon by ... bipartisan and veto-proof vote sends a strong signal ... for providers will not,be held hostage to the ...
... Zuccari,President & CEO of Hamilton Insurance Agency is featured ... Health Care Association this,June for his recent work with ... by the AHCA," said Alan J. Zuccari. "I,am proud ... focus is providing quality care.", Below is the ...
... supply, study suggests , , TUESDAY, June 24 (HealthDay News) ... help reduce a form of brain injury that affects ... study. , Hypoxic-ischemia, a compromise of the brain,s ... and cognitive/behavioral problems. , In experiments with rats that ...
Cached Medicine News:Health News:Function Drinks Launches New Product to Support Sexual Health 2Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 2Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 3Health News:Blue Shield of California Appoints Industry Veteran as New Vice President and General Manager for Senior Market 2Health News:Alan J. Zuccari Featured by the American Health Care Association as a June PAC Member 2Health News:Alzheimer's Drug May Reduce Preemie Brain Injury 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: